Ownership and insider activity for Solid Biosciences Inc. (SLDB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.
Price
| Price | $8.72 |
| Market Cap | $858M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.7M | $52.1M | $86.4M | $76.0M | $154.7M | $119.1M | $155.4M | $74.0M | $80.2M | $59.9M |
| Short-term Investments | $30.0M | $17.0M | $36.1M | $7.5M | 0 | $88.6M | $58.3M | $49.6M | $68.7M | $128.0M |
| Receivables | 0 | 0 | 0 | 0 | 0 | $110000 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $40.0M | $70.7M | $128.6M | $86.3M | $158.9M | $222.6M | $219.6M | $129.7M | $157.3M | $205.5M |
| Property, Plant & Equipment | $452000 | $2.4M | $10.4M | $16.6M | $11.7M | $7.6M | $38.6M | $33.2M | $29.0M | $26.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $40.6M | $76.2M | $139.6M | $103.5M | $171.2M | $232.4M | $260.3M | $164.9M | $188.7M | $232.5M |
| Accounts Payable | $3.0M | $5.1M | $3.7M | $7.1M | $3.3M | $4.5M | $3.2M | $2.0M | $4.2M | $3.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $6.9M | $11.3M | $12.5M | $18.3M | $24.5M | $23.6M | $22.5M | $14.5M | $30.3M | $33.5M |
| Long-term Debt | 0 | 0 | $859000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $78.5M | $135.4M | $14.4M | $23.4M | $39.1M | $24.2M | $48.6M | $38.5M | $51.4M | $52.5M |
| Retained Earnings | -$84.9M | -$124.3M | -$199.1M | -$316.3M | -$404.6M | -$476.8M | -$562.7M | -$658.8M | -$783.5M | -$957.8M |
| Total Equity | -$84.4M | -$59.3M | $125.2M | $80.0M | $132.1M | $208.2M | $211.7M | $126.5M | $137.2M | $180.0M |
| Total Debt | 0 | 0 | $1.9M | $7.1M | $5.2M | $2.1M | $28.5M | $26.3M | $24.2M | $21.2M |
| Net Debt | -$37.7M | -$69.1M | -$120.6M | -$76.5M | -$149.6M | -$205.7M | -$185.2M | -$97.4M | -$124.7M | -$166.7M |
| Working Capital | $33.1M | $59.4M | $116.2M | $68.0M | $134.4M | $199.0M | $197.1M | $115.2M | $127.0M | $172.0M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 13.82 |
Profitability
| Return on Equity | -72.28% |
| Return on Invested Capital | -53.81% |
| Return on Assets | -49.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANNX · AURA · AUTL · BNTC · DSGN · LBRX · NMRA
Explore sector: Healthcare · Biotechnology
More sections of SLDB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks